Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity

COMPANY PROFILE
  • Vector BioMed has expanded its LENTIVERSE™ platform and unveiled a new brand identity to advance global access to gene therapy.
  • The company introduced VectorCraft and LaunchSuite, offering cost-effective and ready-to-deploy lentiviral vector and CAR-T manufacturing solutions.

Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organisation (CVDMO), has announced the expansion of its LENTIVERSE™ platform alongside a new brand identity aimed at accelerating global gene therapy access. The initiative aligns with the company’s mission to make gene therapies more affordable and accessible for patients worldwide.

The LENTIVERSE™ platform integrates decades of expertise in vector development and manufacturing, offering solutions for both CAR-T production and custom vector design. It is structured around two core offerings: VectorCraft, a custom lentivirus development and manufacturing service, and LaunchSuite, a ready-to-deploy solution for generic CAR-T manufacturing. Together, these platforms provide streamlined development workflows, transparent economics, and a potential 50% reduction in CGMP manufacturing costs compared to market averages.

“Vector BioMed spun out of Caring Cross to shift the conversation and relationship developers have with CDMOs. Our new brand embodies our continued commitment to support all that are seeking a path to treat patients by various means.”

Boro Dropulić, PhD MBA, Chief Executive Officer of Vector BioMed

According to the company, LENTIVERSE™ is built upon three pillars: a third-generation lentivirus vector platform, streamlined development and manufacturing with cell manufacturing expertise, and a focus on global accessibility through transparent economics. The system is designed to remove financial and logistical barriers that often limit access to advanced therapies.

The company’s rebrand and newly launched website underscore a commitment to “break down barriers” in cell and gene therapy access, combining visual identity with a digital platform that enhances visibility, transparency, and collaboration.

CDMO News Analysed

The latest CDMO investments, partnerships, and market intelligence. Download for:

  • Full tracker of partnerships and strategic announcements.
  • Deal value of disclosed investment
  • Regional and modality trends